Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic ... CSU is a severe form of hives that affects around 1% of the global population, causing ...
The EMA's human medicines committee (CHMP) has recommended IL-4 and IL-13 inhibitor Dupixent (dupilumab) to treat adults with moderate to severe PN, a disease which causes hard lumps to form on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback